Two Sigma Advisers’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q1
Sell
-147,560
Closed -$4.36M 2275
2014
Q4
$4.36M Buy
147,560
+53,859
+57% +$1.54M 0.03% 524
2014
Q3
$2.63M Sell
93,701
-58,075
-38% -$1.63M 0.02% 720
2014
Q2
$4.27M Sell
151,776
-108,562
-42% -$3.09M 0.03% 528
2014
Q1
$7.93M Sell
260,338
-352,879
-58% -$10.5M 0.07% 295
2013
Q4
$17.8M Buy
613,217
+7,272
+1% +$212K 0.17% 127
2013
Q3
$16.5M Buy
605,945
+503,707
+493% +$13.7M 0.2% 107
2013
Q2
$2.72M Buy
+102,238
New +$2.82M 0.04% 412

Other funds holding PFE

Two Sigma Advisers's PFE Position: Q1 2026 in Review

Two Sigma Advisers sold out of Pfizer (PFE) in Q1 2026, closing a stake of 14,800 shares — an estimated $369K sold.

Two Sigma Advisers first reported a position in PFE in Q2 2013 and held it in 49 quarters. The position peaked at $497M in Q2 2024. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Two Sigma Advisers reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 14,800 Pfizer shares in Q1 2026, an estimated $369K.
  • Two Sigma Advisers first reported a position in Pfizer in Q2 2013 and held it in 49 quarters.
  • Two Sigma Advisers's Pfizer position peaked at $497M in Q2 2024.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.